Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRATE study of rapid versus standard Avastin treat-and-extend for low-risk neovascular age-related macular degeneration
ACTRN12622001246774Phase 4Not yet recruiting
- Sponsor
- Palmerston North Hospital
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in exudative macular degeneration (2 arms), sponsored by Palmerston North Hospital. Primary endpoint: Best corrected visual acuity. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12622001246774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001246774.